Fieldpoint Private Securities LLC lowered its holdings in shares of Novartis AG (NYSE:NVS) by 20.5% during the fourth quarter, HoldingsChannel.com reports. The firm owned 3,700 shares of the company’s stock after selling 957 shares during the quarter. Fieldpoint Private Securities LLC’s holdings in Novartis were worth $311,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. grew its holdings in shares of Novartis by 8.2% during the fourth quarter. BlackRock Inc. now owns 4,015,562 shares of the company’s stock worth $337,146,000 after buying an additional 305,221 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Novartis by 18.8% during the fourth quarter. Renaissance Technologies LLC now owns 1,716,100 shares of the company’s stock worth $144,084,000 after buying an additional 271,900 shares in the last quarter. Amundi Pioneer Asset Management Inc. grew its holdings in shares of Novartis by 228.8% during the third quarter. Amundi Pioneer Asset Management Inc. now owns 317,300 shares of the company’s stock worth $27,240,000 after buying an additional 220,800 shares in the last quarter. Aristotle Capital Management LLC grew its holdings in shares of Novartis by 7.2% during the fourth quarter. Aristotle Capital Management LLC now owns 3,195,134 shares of the company’s stock worth $268,263,000 after buying an additional 215,584 shares in the last quarter. Finally, Senzar Asset Management LLC bought a new position in shares of Novartis during the fourth quarter worth about $17,203,000. 10.76% of the stock is currently owned by institutional investors.
Novartis AG (NVS) opened at $80.62 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.21 and a quick ratio of 0.91. The firm has a market capitalization of $190,170.44, a P/E ratio of 24.99, a price-to-earnings-growth ratio of 1.91 and a beta of 0.78. Novartis AG has a one year low of $72.67 and a one year high of $94.19.
Novartis (NYSE:NVS) last issued its earnings results on Wednesday, January 24th. The company reported $1.20 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.04. Novartis had a return on equity of 16.03% and a net margin of 15.69%. The company had revenue of $12.92 billion during the quarter, compared to the consensus estimate of $12.65 billion. During the same period in the previous year, the company posted $1.14 EPS. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. equities research analysts predict that Novartis AG will post 5.36 EPS for the current year.
A number of research analysts recently issued reports on the company. Nord/LB reiterated a “neutral” rating on shares of Novartis in a report on Tuesday, January 2nd. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis in a report on Thursday, January 18th. UBS reiterated a “neutral” rating on shares of Novartis in a report on Monday, January 15th. Bank of America downgraded Novartis from a “neutral” rating to an “underperform” rating in a report on Wednesday, December 6th. Finally, Zacks Investment Research downgraded Novartis from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $87.51.
WARNING: “Fieldpoint Private Securities LLC Has $311,000 Holdings in Novartis AG (NVS)” was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.thestockobserver.com/2018/03/20/fieldpoint-private-securities-llc-has-311000-holdings-in-novartis-ag-nvs.html.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.